Fool.co.uk: Stock Investing Advice | Stock Research
 
 

  Print   

Monday 24 November, 2003

GlaxoSmithKline PLC

Augmentin Patent Case Ruling

GlaxoSmithKline PLC
23 November 2003

               US Court of Appeals Rules in Augmentin Patent Case


LONDON, November 21, 2003 -- GlaxoSmithKline (GSK) today announced that the US
Court of Appeals for the Federal Circuit in Washington, DC has ruled in favour
of Geneva Pharmaceuticals, Teva Pharmaceuticals and Ranbaxy, and upheld lower
court rulings that invalidated GSK's US patents for its antibiotic Augmentin.

GSK continues to be committed to its newer Augmentin antibiotic medicines --
Augmentin ES and XR-- which now represent nearly 35% of the total number of
prescriptions being written for branded and generic Augmentin.


S M Bicknell

Company Secretary

21st November 2003


About GSK:

GlaxoSmithKline, one of the world's leading research-based pharmaceutical and
healthcare companies, is committed to improving the quality of human life by
enabling people to do more, feel better and live longer. For more information,
please visit the company's web site at www.gsk.com.

Inquiries:

US Media Inquiries:                Nancy Pekarek               (215) 751 7709
                                   Mary Anne Rhyne             (919) 483 2839
                                   Patricia Seif               (215) 751 7709

UK Media Inquiries:                Martin Sutton               (020) 8047 5502
                                   Chris Hunter-Ward           (020) 8047 5502
                                   David Mawdsley              (020) 8047 5502

European Analyst/
Investor enquiries:                Duncan Learmouth            (020) 8047 5540
                                   Anita Kidgell               (020) 8047 5542
                                   Philip Thomson              (020) 8047 5543

US Analyst/ Investor enquiries:    Frank Murdolo               (215) 751 7002
                                   Tom Curry                   (215) 751 5419




                      This information is provided by RNS
            The company news service from the London Stock Exchange

Investegate takes no responsibility for the accuracy of the information within the site.


The announcements are supplied by the denoted source. Queries about the content of an announcement should be directed to the source. Investegate reserves the right to publish a filtered set of announcements. NAV, EMM/EPT, Rule 8 and FRN Variable Rate Fix announcements are filitered from this site.


Investegate      © 2012 Financial Express. All rights reserved.